Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer

Fu Tsai Chung, Kang Yun Lee, Yueh Fu Fang, Meng Heng Shieh, Shu Min Lin, Chih Teng Yu, Yun Lun Lo, Ting Yu Lin, Chih Hsi Kuo, Po Hao Feng, Yung Lun Ni, Han Pin Kuo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: Docetaxel and pemetrexed have been validated as therapeutics for previously treated advanced non-small-cell lung cancer (NSCLC), but tolerability is a concern for standard treatment with docetaxel administered once every 3 weeks (tri-weekly 75-mg/m2 schedule). We conducted this retrospective study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC. Methods: Consecutive patients who received low-dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks) or pemetrexed (500 mg/m 2 every 3 weeks) at a single university-affiliated hospital following failure of previous treatment were retrospectively reviewed. Their outcomes and toxicity profiles were determined. Results: 179 patients were included between 2005 and 2008 (docetaxel, n = 79; pemetrexed, n = 100). Both groups had similar hematologic (16.5 vs. 15.0%; p = 0.84) and non-hematologic (20.3 vs. 24%; p = 0.55) toxicities. After controlling for confounding factors, docetaxel remained superior to pemetrexed for progression-free survival (median 4.0 vs. 2.4 months; hazard ratio 0.64; 95% CI 0.47-0.87; p = 0.005) and overall survival (median 15.0 vs.8.5 months; hazard ratio 0.54; 95% CI 0.38-0.77; p

Original languageEnglish
Pages (from-to)147-155
Number of pages9
JournalChemotherapy
Volume57
Issue number2
DOIs
Publication statusPublished - Apr 2011
Externally publishedYes

Fingerprint

docetaxel
Pemetrexed
Non-Small Cell Lung Carcinoma
Treatment Failure
Disease-Free Survival
Appointments and Schedules
Retrospective Studies

Keywords

  • Advanced non-small-cell lung cancer
  • Docetaxel
  • Pemetrexed

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. / Chung, Fu Tsai; Lee, Kang Yun; Fang, Yueh Fu; Shieh, Meng Heng; Lin, Shu Min; Yu, Chih Teng; Lo, Yun Lun; Lin, Ting Yu; Kuo, Chih Hsi; Feng, Po Hao; Ni, Yung Lun; Kuo, Han Pin.

In: Chemotherapy, Vol. 57, No. 2, 04.2011, p. 147-155.

Research output: Contribution to journalArticle

Chung, Fu Tsai ; Lee, Kang Yun ; Fang, Yueh Fu ; Shieh, Meng Heng ; Lin, Shu Min ; Yu, Chih Teng ; Lo, Yun Lun ; Lin, Ting Yu ; Kuo, Chih Hsi ; Feng, Po Hao ; Ni, Yung Lun ; Kuo, Han Pin. / Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. In: Chemotherapy. 2011 ; Vol. 57, No. 2. pp. 147-155.
@article{cb0082b4901a4ddd906f034a16f6b529,
title = "Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer",
abstract = "Objectives: Docetaxel and pemetrexed have been validated as therapeutics for previously treated advanced non-small-cell lung cancer (NSCLC), but tolerability is a concern for standard treatment with docetaxel administered once every 3 weeks (tri-weekly 75-mg/m2 schedule). We conducted this retrospective study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC. Methods: Consecutive patients who received low-dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks) or pemetrexed (500 mg/m 2 every 3 weeks) at a single university-affiliated hospital following failure of previous treatment were retrospectively reviewed. Their outcomes and toxicity profiles were determined. Results: 179 patients were included between 2005 and 2008 (docetaxel, n = 79; pemetrexed, n = 100). Both groups had similar hematologic (16.5 vs. 15.0{\%}; p = 0.84) and non-hematologic (20.3 vs. 24{\%}; p = 0.55) toxicities. After controlling for confounding factors, docetaxel remained superior to pemetrexed for progression-free survival (median 4.0 vs. 2.4 months; hazard ratio 0.64; 95{\%} CI 0.47-0.87; p = 0.005) and overall survival (median 15.0 vs.8.5 months; hazard ratio 0.54; 95{\%} CI 0.38-0.77; p",
keywords = "Advanced non-small-cell lung cancer, Docetaxel, Pemetrexed",
author = "Chung, {Fu Tsai} and Lee, {Kang Yun} and Fang, {Yueh Fu} and Shieh, {Meng Heng} and Lin, {Shu Min} and Yu, {Chih Teng} and Lo, {Yun Lun} and Lin, {Ting Yu} and Kuo, {Chih Hsi} and Feng, {Po Hao} and Ni, {Yung Lun} and Kuo, {Han Pin}",
year = "2011",
month = "4",
doi = "10.1159/000321037",
language = "English",
volume = "57",
pages = "147--155",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer

AU - Chung, Fu Tsai

AU - Lee, Kang Yun

AU - Fang, Yueh Fu

AU - Shieh, Meng Heng

AU - Lin, Shu Min

AU - Yu, Chih Teng

AU - Lo, Yun Lun

AU - Lin, Ting Yu

AU - Kuo, Chih Hsi

AU - Feng, Po Hao

AU - Ni, Yung Lun

AU - Kuo, Han Pin

PY - 2011/4

Y1 - 2011/4

N2 - Objectives: Docetaxel and pemetrexed have been validated as therapeutics for previously treated advanced non-small-cell lung cancer (NSCLC), but tolerability is a concern for standard treatment with docetaxel administered once every 3 weeks (tri-weekly 75-mg/m2 schedule). We conducted this retrospective study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC. Methods: Consecutive patients who received low-dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks) or pemetrexed (500 mg/m 2 every 3 weeks) at a single university-affiliated hospital following failure of previous treatment were retrospectively reviewed. Their outcomes and toxicity profiles were determined. Results: 179 patients were included between 2005 and 2008 (docetaxel, n = 79; pemetrexed, n = 100). Both groups had similar hematologic (16.5 vs. 15.0%; p = 0.84) and non-hematologic (20.3 vs. 24%; p = 0.55) toxicities. After controlling for confounding factors, docetaxel remained superior to pemetrexed for progression-free survival (median 4.0 vs. 2.4 months; hazard ratio 0.64; 95% CI 0.47-0.87; p = 0.005) and overall survival (median 15.0 vs.8.5 months; hazard ratio 0.54; 95% CI 0.38-0.77; p

AB - Objectives: Docetaxel and pemetrexed have been validated as therapeutics for previously treated advanced non-small-cell lung cancer (NSCLC), but tolerability is a concern for standard treatment with docetaxel administered once every 3 weeks (tri-weekly 75-mg/m2 schedule). We conducted this retrospective study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC. Methods: Consecutive patients who received low-dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks) or pemetrexed (500 mg/m 2 every 3 weeks) at a single university-affiliated hospital following failure of previous treatment were retrospectively reviewed. Their outcomes and toxicity profiles were determined. Results: 179 patients were included between 2005 and 2008 (docetaxel, n = 79; pemetrexed, n = 100). Both groups had similar hematologic (16.5 vs. 15.0%; p = 0.84) and non-hematologic (20.3 vs. 24%; p = 0.55) toxicities. After controlling for confounding factors, docetaxel remained superior to pemetrexed for progression-free survival (median 4.0 vs. 2.4 months; hazard ratio 0.64; 95% CI 0.47-0.87; p = 0.005) and overall survival (median 15.0 vs.8.5 months; hazard ratio 0.54; 95% CI 0.38-0.77; p

KW - Advanced non-small-cell lung cancer

KW - Docetaxel

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=79953215730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953215730&partnerID=8YFLogxK

U2 - 10.1159/000321037

DO - 10.1159/000321037

M3 - Article

C2 - 21454972

AN - SCOPUS:79953215730

VL - 57

SP - 147

EP - 155

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 2

ER -